Business & Decision Life Sciences (BDLS), which provides clinical-research and consulting services to life-science clients in North America and Europe, has secured valuable resources for non-interventional studies by acquiring Paris, France-based specialist Ceri Medical.
No financial details were available on the deal, under which Ceri Medical’s management will join the senior leadership team of an expanded BDLS. Ceri has over 20 years’ experience in designing, running and reporting epidemiological and observational studies, generating turnover of more than €1.5 million in its last full year.
Xavier Gobert, chief strategy officer at Business & Decision Life Sciences, cited the increasing focus on cost/benefit analyses of life-science products by government agencies and institutional payers.
Burden and causes
“Business & Decision Life Sciences’ contract research organisation is helping our customers to reduce the time and cost of drug development,” Gobert noted.
“Ceri Medical’s epidemiological capabilities will further differentiate and enhance our services to help our worldwide customers better understand the burden and causes of health problems in human populations.”
In addition, Ceri Medical’s well-established presence in France (its headquarters are in Paris) will broaden BDLS’s existing capabilities “in this important market”, Gobert said.
Based in Brussels, BDLS is part of the Business & Decision Group, an international consulting and systems-integration company set up in 1992.
Among BDLS’s core capabilities are operational, data-management, analytical, outcomes-research and document-writing support for clinical trials, as well as technology-based clinical applications and solutions tailored to the life-sciences industry.
Integrating with BDLS will supplement Ceri’s expertise in non-interventional studies with “the support platform of a well-respected, biometrics specialist contract research organisation that, through its approach to study conduct, will allow our clients to benefit through greater cost savings”, commented Dr Serge Bergal, chief executive officer of Ceri Medical.